Health Care·Life Sciences Tools & Services·$6.6B
Repligen Corp (RGEN) operates in the health care sector, specifically within life sciences tools and services. The company focuses on providing innovative solutions for the bioprocessing industry, which is crucial for the production of biologics and pharmaceuticals.
EPS
Earnings per share is a key indicator of profitability, and investors will closely watch if RGEN meets or exceeds the consensus estimate.
Revenue
Revenue growth reflects the company's ability to expand its market presence and drive sales, which is vital for investor confidence.
Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
2Q
EPS Beat Rate
75%
Avg EPS Surprise
+7.41%
Avg Stock Reaction
+2.82%
In the last quarter, Repligen reported an EPS of $0.49, surpassing estimates by 11.36%. However, the stock experienced a slight decline the following day, indicating mixed investor sentiment.
Management Promises & Guidance
Analysts expect Repligen to deliver solid earnings this quarter, with a consensus EPS of $0.38. Investors are particularly focused on revenue growth to gauge the company's market performance.
Bull Case
If Repligen exceeds the EPS and revenue estimates, it could signal strong demand for its products and boost investor confidence, potentially leading to a significant stock price increase.
Bear Case
Conversely, if the company fails to meet expectations, especially in revenue, it could raise concerns about its growth trajectory and lead to a decline in stock price.
EPS
0.38Earnings per share is a key indicator of profitability, and investors will closely watch if RGEN meets or exceeds the consensus estimate.
Revenue
192MRevenue growth reflects the company's ability to expand its market presence and drive sales, which is vital for investor confidence.
The print will turn on these two things.
Q1
Will Repligen achieve an EPS of $0.38 or higher?
This figure is critical as it reflects the company's profitability and can significantly influence investor sentiment.
Q2
What is the revenue figure for this quarter?
Revenue growth is essential for assessing the company's market performance and future prospects.
Why consensus could be wrong
The consensus may underestimate Repligen's growth potential due to its recent product innovations and expanding market share, which could drive better-than-expected results.
Supporting Evidence
Repligen has consistently beaten EPS estimates in 75% of the last eight quarters, indicating strong operational performance.
The company has a history of positive revenue surprises, suggesting potential for exceeding current expectations.
Key Risk
If revenue growth significantly outpaces expectations, it could challenge the current bearish sentiment.
Pre-commit to what would confirm each case.
This quarter's performance is under scrutiny as it will indicate whether Repligen can sustain its growth trajectory amid market challenges.
Bull Confirmed If
Achieving an EPS of $0.40 or higher with revenue exceeding $195M would confirm strong operational performance.
Bear Confirmed If
An EPS below $0.37 or revenue falling short of $188M would raise concerns about growth and profitability.
Implied Move
±N/A
There is no options market data available to gauge investor sentiment ahead of the earnings report.
Likely market behavior by outcome — not investment advice.
Beat & Raise
If Repligen beats expectations, history suggests the stock could rise by around 3.57%, confirming strong demand for its products.
In-Line / Cautious
If results are in line with expectations, the stock may see muted movement as investors await further guidance from management.
Miss
A miss could lead to a decline of about 0.58%, reflecting investor disappointment and concerns about future growth.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
PARAMOUNT SKYDANCE C Class B
May 4, 2026